Concord Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE858L01010
NSEID:
BSEID: 538965

INR

77.80

0.5 (0.65%)

BSENSE

Dec 05

BSE+NSE Vol: 203

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Concord Drugs

Sunil Healthcare

Welcure Drugs

Source Natural

Ajooni Biotech

Samrat Pharma

Makers Labs.

Rajnish Wellness

Asston Pharmaceu

Amwill Health

Kabra Drugs

Why is Concord Drugs Ltd ?

Weak Long Term Fundamental Strength with a -12.22% CAGR growth in Operating Profits over the last 5 years

Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.63 times
The company has been able to generate a Return on Equity (avg) of 2.23% signifying low profitability per unit of shareholders funds

Flat results in Sep 25

NET SALES(Q) Lowest at Rs 10.28 cr

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Concord Drugs for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Concord Drugs

104.74%

1.73

60.55%

Sensex

4.55%

0.38

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

3.17%

EBIT Growth (5y)

-12.22%

EBIT to Interest (avg)

1.44

Debt to EBITDA (avg)

5.93

Net Debt to Equity (avg)

0.49

Sales to Capital Employed (avg)

0.85

Tax Ratio

43.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

4.56%

ROE (avg)

2.23%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

134

Industry P/E

Price to Book Value

2.25

EV to EBIT

30.52

EV to EBITDA

20.73

EV to Capital Employed

1.84

EV to Sales

2.09

PEG Ratio

0.63

Dividend Yield

ROCE (Latest)

6.04%

ROE (Latest)

1.69%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

PAT(9M)

Higher at Rs 0.35 Cr

-4What is not working for the Company

NET SALES(Q)

Lowest at Rs 10.28 cr

Loading Valuation Snapshot...

Here's what is working for Concord Drugs

Profit After Tax (PAT) - Nine Monthly

Higher at Rs 0.35 Cr

than preceding 12 month period ended Sep 2025 of Rs -0.04 cr

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Concord Drugs

Net Sales - Quarterly

At Rs 10.28 cr has Fallen at -16.90%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (Rs Cr)

Net Sales - Quarterly

Lowest at Rs 10.28 cr

in the last five quarters

MOJO Watch

Near term sales trend is negative

Net Sales (Rs Cr)